

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

November 20, 2023

**Chordia Announces Completion of Patient Enrollment in the Phase 1 Study for Solid Tumors and Hematologic Malignancies in Japan.**

Kanagawa, Japan, November 20, 2023 – Chordia Therapeutics Inc. (Chordia) is pleased to announce the completion of patient enrollment in the Phase 1 clinical trial of CTX-712, a selective pan-CDC2-like kinase inhibitor, in patients with solid tumors and hematologic malignancies in Japan. Through collaboration with universities, research institutes, and companies in the healthcare industry, we will continue to research and develop anti-cancer drugs, with the aim of creating new, innovative drugs.

For more information, please refer to jRCT2080224127

Please visit: [Japan Registry of Clinical Trials](#)

**About CTX-712**

CTX-712 is a first-in-class, orally available, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process that plays an important role in cell growth. CTX-712 inhibits the growth of various human tumor cell lines *in vitro*, and in addition, exhibits antitumor activity in multiple xenograft mouse models *in vivo*. In addition to the Phase 1 clinical trial in Japan, the Phase 1/2 clinical trial in the United States is ongoing. For more information on the Phase 1/2 clinical trial in the United States, please visit: [clinicaltrials.gov/](https://clinicaltrials.gov/) (NCT05732103).

**Important Notice**

In this press release, the definition of “press release” covers any oral presentation, question, and answer session, and written and/or oral materials discussed or distributed by Chordia Therapeutics in connection with this press release. This press release (including the oral description and related questions and answers) is not intended to constitute, represent, or form part of any offer, invitation, or solicitation to purchase and/or acquire anything, including securities.

**Disclaimer**

Any announcements by Chordia Therapeutics, including this press release, may contain information on products derived from pharmaceutical developments, but are intended to inform the latest information related to Chordia’s business, and not intended as promotions, solicitations, advertisements, or to provide medical advice.

---

### **Forward-Looking Statements**

This press release and materials distributed in connection with this press release may contain forward-looking statements, information, beliefs, and opinions concerning our future operations, future positioning, and performance, including estimates, projections, goals, and plans. Forward-looking statements may include, but are not limited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues," "expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates," "projects," and/or other similar expressions, or the negative thereof. These forward-looking statements are based on assumptions concerning a number of important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements; highly influential factors that include economic conditions surrounding our global business, which include general economic conditions in Japan and the United States, competitive pressures and developments including changes in applicable laws and regulations, which include global healthcare reform, uncertainty as to our clinical success, and challenges inherent in new product development (which include regulatory decisions and their timing,) uncertainty as to the commercial success of new and existing products manufacturing difficulties, delays fluctuations in interest rates and exchange rates claims or concerns regarding the safety or efficacy of commercial products or product candidates the impact of a health crisis, such as the COVID-19 pandemic, on Chordia and its customers and suppliers (including foreign governments in countries in which the Company conducts business) or other aspects of its business. We undertake no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements we may make, except as required by law or stock exchange rules. Past performance is not indicative of future operating results, and any of our operating results or statements in this press release are not estimates, forecasts, warranties, or projections of our future operating results.

### **About Chordia Therapeutics**

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers. Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan and Phase1/2 clinical study in US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR, Mizobe: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)